Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × Anti-Bacterial Agents × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Surgical Wound Infection 4 Neoplasms 4 Colorectal Neoplasms 3 Rectal Neoplasms 2 Pancreatic Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Skin Neoplasms 1 Sepsis 1 Pancreatic Fistula 1 Neutropenia 1 Neoplasms, Plasma Cell 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Melanoma 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Intestinal Neoplasms 1 Inflammation 1 Infections 1 Hematologic Neoplasms 1 Glioblastoma 1 Fever 1 Febrile Neutropenia 1 Exanthema 1 Emergencies 1 Duodenal Neoplasms 1 Discitis 1

Interventions

pembrolizumab 256 Nivolumab 228 Ipilimumab 208 Cyclophosphamide 125 aldesleukin 123 Interleukin-2 92 Dacarbazine 68 trametinib 66 Temozolomide 66 fludarabine 64 Vemurafenib 63 dabrafenib 59 fludarabine phosphate 56 Radiosurgery 43 sargramostim 40 Biopsy 40 Bevacizumab 39 binimetinib 38 incomplete Freund's adjuvant 37 Paclitaxel 35 Cisplatin 34 Radiotherapy 33 encorafenib 31 atezolizumab 31 cobimetinib 30 Magnetic Resonance Spectroscopy 30 Carboplatin 29 Introns 28 Specimen Handling 27 CTLA-4 Antigen 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03817125 2024-06-06

MCGRAW

Parker Institute for Cancer Immunotherapy

Phase 1 Completed

14 enrolled 22 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡